MIM
SPRY icon

MetLife Investment Management’s ARS Pharmaceuticals SPRY Stock Holding History

MetLife Investment Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$294K Buy
36,644
+2,306
+7% +$19.8K ﹤0.01% 2216
2026
Q1 		$276K Hold
34,338
– – ﹤0.01% 2053
2025
Q4 		$400K Hold
34,338
– – ﹤0.01% 1897
2025
Q3 		$345K Buy
34,338
+1,561
+5% +$22.4K ﹤0.01% 2001
2025
Q2 		$572K Buy
32,777
+342
+1% +$4.93K ﹤0.01% 1611
2025
Q1 		$408K Sell
32,435
-651
-2% -$7.83K ﹤0.01% 1820
2024
Q4 		$349K Buy
33,086
+3,769
+13% +$52.8K ﹤0.01% 1990
2024
Q3 		$425K Hold
29,317
– – ﹤0.01% 1865
2024
Q2 		$249K Buy
29,317
+15,533
+113% +$138K ﹤0.01% 2110
2024
Q1 		$141K Hold
13,784
– – ﹤0.01% 2374
2023
Q4 		$75.5K Hold
13,784
– – ﹤0.01% 2715
2023
Q3 		$52.1K Hold
13,784
– – ﹤0.01% 2825
2023
Q2 		$92.4K Buy
+13,784
New +$92K ﹤0.01% 2725
2021
Q4 		– Sell
-9,098
Closed -$90.8K – 2549
2021
Q3 		$90.8K Buy
9,098
+3,571
+65% +$88.1K ﹤0.01% 2478
2021
Q2 		$171K Hold
5,527
– – ﹤0.01% 2250
2021
Q1 		$241K Buy
+5,527
New +$262K ﹤0.01% 1954

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

MetLife Investment Management's SPRY Position: Q2 2026 in Review

MetLife Investment Management increased its ARS Pharmaceuticals (SPRY) stake by 6.7% in Q2 2026, buying an estimated $19.8K and bringing the position to 36,644 shares worth $294K. The position accounts for ﹤0.01% of the portfolio, ranked #2216.

MetLife Investment Management first reported a position in SPRY in Q1 2021 and has held it in 16 quarters since. The position peaked at $572K in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • MetLife Investment Management held 36,644 shares of ARS Pharmaceuticals worth $294K as of Q2 2026.
  • MetLife Investment Management bought 2,306 ARS Pharmaceuticals shares in Q2 2026, an estimated $19.8K.
  • ARS Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2216 holding.
  • MetLife Investment Management first reported a position in ARS Pharmaceuticals in Q1 2021 and has held it in 16 quarters since.
  • MetLife Investment Management's ARS Pharmaceuticals position peaked at $572K in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.